Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer
Eagle Pharmaceuticals (OTCMKTS: EGRX) has appointed Christopher Krawtschuk as Chief Financial Officer, effective November 11, 2024. Krawtschuk replaces Steven Ratoff, who steps down as interim CFO but remains on the company's board. Krawtschuk brings extensive pharmaceutical sector experience, having previously served as CFO at bluebird bio and Jubilant Pharma. His background includes roles at Morphosys, where he helped build U.S. commercial operations, and Pfizer, where he provided financial leadership. He began his career at PricewaterhouseCoopers, holds a B.S. in Accounting, and is a licensed CPA.
Eagle Pharmaceuticals (OTCMKTS: EGRX) ha nominato Christopher Krawtschuk come Direttore finanziario, con effetto dall'11 novembre 2024. Krawtschuk sostituisce Steven Ratoff, che si dimette dal ruolo di CFO ad interim ma rimane nel consiglio della società. Krawtschuk porta con sé una vasta esperienza nel settore farmaceutico, avendo precedentemente ricoperto il ruolo di CFO presso bluebird bio e Jubilant Pharma. La sua carriera include ruoli in Morphosys, dove ha contribuito a costruire le operazioni commerciali negli Stati Uniti, e presso Pfizer, dove ha fornito leadership finanziaria. Ha iniziato la sua carriera presso PricewaterhouseCoopers, possiede una laurea in Contabilità ed è un CPA certificato.
Eagle Pharmaceuticals (OTCMKTS: EGRX) ha nombrado a Christopher Krawtschuk como Director Financiero, con efecto a partir del 11 de noviembre de 2024. Krawtschuk reemplaza a Steven Ratoff, quien renuncia como CFO interino pero permanece en la junta de la compañía. Krawtschuk aporta una amplia experiencia en el sector farmacéutico, habiendo ocupado anteriormente el cargo de CFO en bluebird bio y Jubilant Pharma. Su experiencia incluye roles en Morphosys, donde ayudó a construir operaciones comerciales en EE. UU., y en Pfizer, donde proporcionó liderazgo financiero. Comenzó su carrera en PricewaterhouseCoopers, posee una licenciatura en Contabilidad y es un CPA con licencia.
이글 제약 (OTCMKTS: EGRX)가 크리스토퍼 크라우츠척을 최고재무책임자(CFO)로 임명했습니다. 이는 2024년 11월 11일부터 효력이 발생합니다. 크라우츠척은 중간 CFO직에서 물러나는 스티븐 라토프를 대신하게 되며, 그는 회사 이사회에 남아 있습니다. 크라우츠척은 블루버드 바이오와 주빌란트 제약에서 CFO로 활동하는 등 제약 부문에서 광범위한 경험을 가지고 있습니다. 그는 모포시스에서 미국 상업 운영 구축을 도왔으며, 화이자에서는 재무 리더십을 제공했습니다. 크라우츠척은 프라이스워터하우스쿠퍼스에서 경력을 시작했으며, 회계학 학사 학위를 소지하고 있고, CPA 자격증을 보유하고 있습니다.
Eagle Pharmaceuticals (OTCMKTS: EGRX) a nommé Christopher Krawtschuk au poste de Directeur Financier, à compter du 11 novembre 2024. Krawtschuk remplace Steven Ratoff, qui se retire de son poste de CFO par intérim mais reste au conseil d'administration de l'entreprise. Krawtschuk apporte une vaste expérience dans le secteur pharmaceutique, ayant précédemment exercé comme CFO chez bluebird bio et Jubilant Pharma. Son parcours inclut des rôles chez Morphosys, où il a contribué à établir les opérations commerciales aux États-Unis, et chez Pfizer, où il a assuré le leadership financier. Il a commencé sa carrière chez PricewaterhouseCoopers, détient un B.S. en comptabilité et est un CPA agréé.
Eagle Pharmaceuticals (OTCMKTS: EGRX) hat Christopher Krawtschuk zum Finanzvorstand ernannt, der am 11. November 2024 in Kraft tritt. Krawtschuk tritt die Nachfolge von Steven Ratoff an, der als Interim-CFO zurücktritt, aber im Vorstand des Unternehmens bleibt. Krawtschuk bringt umfangreiche Erfahrung im Pharmasektor mit und war zuvor CFO bei bluebird bio und Jubilant Pharma. Seine berufliche Laufbahn umfasst Positionen bei Morphosys, wo er half, die US-Vertriebsteams aufzubauen, und bei Pfizer, wo er finanzielle Führung leistete. Er begann seine Karriere bei PricewaterhouseCoopers, hat einen Bachelor-Abschluss in Rechnungswesen und ist ein lizenzierter CPA.
- Appointment of experienced pharmaceutical sector CFO with proven track record
- New CFO brings specific expertise in capital deployment and structure optimization
- Previous interim CFO remains on board, ensuring continuity in leadership
- None.
WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the appointment of Christopher Krawtschuk as Chief Financial Officer (“CFO”) of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company’s board of directors.
“Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team,” said Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals. “His experience guiding companies through transitional periods brings a valuable perspective to Eagle.”
“Joining Eagle Pharmaceuticals at this time represents a unique opportunity to contribute to the Company,” said Christopher Krawtschuk. “I look forward to working with Michael and his talented colleagues as we strive to execute on our operational priorities.”
Most recently, Mr. Krawtschuk served as CFO and Treasurer of bluebird bio. Prior to that, Mr. Krawtschuk served as CFO of Jubilant Pharma, where he implemented its capital deployment strategy and optimized its capital structure. Prior to Jubilant, in his role as U.S. CFO and Treasurer at Morphosys, a German company, Mr. Krawtschuk helped build a U.S. commercial presence focused on oncology. Prior to that, Mr. Krawtschuk served as lead divisional controller for Pfizer, where he provided financial leadership that supported business strategy, operational performance, and business development efforts. Mr. Krawtschuk began his financial career at PricewaterhouseCoopers where he held several positions of increasing responsibility from 2001 to 2016. Mr. Krawtschuk received his B.S. in Accounting from William Paterson University and is licensed as a CPA.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “could,” “may,” “intend,” “remain,” “regain,” “maintain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “seek,” “continue,” “goal,” “estimate,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements with respect to Mr. Krawtschuk’s expected contributions to the Company and the Company’s ability to execute on its operational priorities. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the completion of the review and preparation of the Company’s financial information and internal control over financial reporting and disclosure controls and procedures and the timing thereof; the discovery of additional information; further delays in the Company’s financial reporting, including as a result of unanticipated factors; the Company’s ability to obtain resolution with respect to the events of default under its Third Amended and Restated Credit Agreement, as amended; the Company's ability to obtain financing and the timing and potential terms thereof; whether the objectives of the Company's review of potential financing and other alternatives will be achieved, the terms, structure, benefits and costs of any arrangement or transaction resulting therefrom, and whether any transaction will be consummated at all; the extent to which the rights under the Company’s stockholder rights agreement become exercisable, if at all; the risk that the Company's review of potential financing and other alternatives and its announcement could have an adverse effect on the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with customers, suppliers, employees, stockholders and other relationships and on its operating results and business generally; the risk that the review of potential financing and other alternatives could divert the attention and time of the Company’s management; the costs resulting from the review of potential financing and other alternatives; the risk of the Company potentially seeking protection under bankruptcy laws; the possibility that the Company will be unable to re-list its common stock on the Nasdaq or another exchange and, if re-listed, the possibility that the Company thereafter will be unable to comply with the listing rules of such exchange; the limitations on trading of the Company’s common stock related to the Company’s trading on the OTC Expert Market; the impact on the price of the Company’s common stock and the Company’s reputation; the Company’s ability to remediate material weaknesses in its internal control over financial reporting; the Company’s ability to recruit and hire a new Chief Executive Officer and retain key personnel; the ability of the Company to realize the anticipated benefits of its plan designed to improve operational efficiencies and realign its sales and marketing expenditures and the impacts thereof; the Company’s reliance on third parties to manufacture commercial supplies of its products and clinical supplies of its product candidates; the impacts of geopolitical factors such as the conflicts between Russia and Ukraine and Hamas, Iran and Israel; delay in or failure to obtain regulatory approval of the Company’s or its partners’ product candidates and successful compliance with Federal Drug Administration, European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether the Company can successfully market and commercialize its products; the success of the Company's relationships with its partners; the outcome of litigation and other legal proceedings and the risk of additional litigation and legal proceedings, including with respect to the matters referenced herein; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and competition from generic entrants into the market; unexpected safety or efficacy data observed during clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the risks inherent in drug development and in conducting clinical trials; risks inherent in estimates or judgments relating to the Company’s critical accounting policies, or any of the Company’s estimates or projections, which may prove to be inaccurate; unanticipated factors in addition to the foregoing that may impact the Company’s financial and business projections and may cause the Company’s actual results and outcomes to materially differ from its estimates and projections; and those risks and uncertainties identified in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023, the Company’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on May 9, 2023, and for the quarter ended June 30, 2023, filed with the SEC on August 8, 2023, and its subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Timothy McCarthy, CFA
T: 917-679-9282
E: tim@lifesciadvisors.com
FAQ
Who is the new CFO of Eagle Pharmaceuticals (EGRX)?
What is Christopher Krawtschuk's previous experience before joining Eagle Pharmaceuticals (EGRX)?